MicroRNA-137-3p Improves Nonalcoholic Fatty Liver Disease through Activating AMPKα

Figure 2

miR-137-3p antagomir aggravates HFD-induced NAFLD in mice. (a) For miR-137-3p inhibition, mice were intraperitoneally injected with the miR-137-3p antagomir or antagomir control (100 mg/kg weekly) for 6 consecutive weeks before being sacrificed. Relative miR-137-3p level in the liver from mice with or without miR-137-3p antagomir injection (). (b) Body weight in mice after 24 weeks of HFD feeding (). (c) The weights of epididymal and inguinal fat pad in mice after 24 weeks of HFD feeding (). (d, e) Serum parameters of FBG and insulin in mice (). (f) Quantification of the insulin resistance index HOMA-IR (). (g) Serum parameters of TG and TC in mice (). (h) Hepatic lipid accumulation as determined by the TG, TC, and NEFA levels (). (i, j) Quantification of the liver weight and LW/TL (). (k) Hepatic hydroxyproline level (). (l) Relative mRNA levels of Col1α1, Col3α1, CTGF, and TGF-β1 in the liver (). (m) Serum ALT and AST levels (). Data were expressed as the , and was considered significant.